GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] we are measuring CagriSema at the wrong time and calling it noise — 24 comments in the full submission. View in context.
190
c/cagrilintide·submitted 8 months ago by u/aa_analysis_andy

[Discussion] we are measuring CagriSema at the wrong time and calling it noise

Discussionbranch of 7 comments

we are measuring CagriSema at the wrong time and calling it noise. I have gone back and forth on this for months. Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved. Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different…

Read the full submission and all 24 comments →

This branch

7 comments, started 8 months ago
u/incretin_ivyMOD18 points·8 months ago

Left up. Thin evidence base, honestly labelled, which is the standard here.

replysharereportpermalink
u/georgi_chowdhury4 points·8 months ago

Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.

replysharereportpermalink
u/slow_logbook_notes301 point·8 months ago

Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.

replysharereportpermalink
u/incretin_ivypharmacology5 points·8 months ago

I would not extrapolate the tolerability profile from the monotherapy arm to the combination. The trials report them separately for a reason.

replysharereportpermalink
u/noor_hovland4 points·8 months ago

nothing containing this is approved as a standalone product

replysharereportpermalink
u/liv_dumitru4 points·8 months ago

Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.

replysharereportpermalink
u/nl_verzekering3 points·8 months ago

Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.

replysharereportpermalink

← back to the whole thread

About c/cagrilintide

Amylin analog pharmacology and the CagriSema combination: why amylin and GLP-1 co-agonism produces a different satiety profile, the REDEFINE readouts, and the very limited pool of people handling cagrilintide as research material.

19kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.comSponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
More in c/cagrilintide
c/cagrilintide rules
  1. Amylin is not a GLP-1. Posts conflating them get corrected.
  2. CagriSema ratios in trials are fixed-dose. Do not extrapolate to self-mixing.
  3. Not approved anywhere. Keep posts descriptive, not instructional.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/amylin_amyu/incretin_ivyu/ledger_mod
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →